Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported third-quarter earnings that surpassed expectations, boosted by robust sales of its key innovative therapies and an improved full-year outlook. Shares surged more than 17% in intra-day trading on Wednesday. The company posted adjusted earnings of $0.78 per share, well above analyst forecasts of $0.68. Revenue rose 3% year over year to $4.48 billion, exceeding the $4.36 billion consensus estimate and representing 1% growth in local currency. Teva’s inn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 124 Dv ...

Welcome back. Take a look at shares of Teva Pharmaceuticals surging this morning after delivering a beat across the board in Q3, pointing to strength in their branded drug portfolio, which contains treatments for schizophrenia, for migraines, and more. Joining us here first on CNBC is Tea CEO Richard Francis.Big move up for for the stock. Uh you lowered the high end of the revenue guidance, raised the low end of the earnings guidance. What what what's driving the strength.>> Hi Sarah, firstly, thank you for ...

Teva Pharmaceutical Industries Limited (TEVA) shares surged 24.91 percent to $21.75 on Wednesday after the company reported a return to profitability for the third quarter.The pharmaceutical company reported a net profit of $433 million, or $0.37 per share, as opposed to a net loss of $437 million, or $0.39 per share, during the same time last year. Net revenue increased 1 percent in local currency terms and 3 percent to $4.48 billion from $4.33 billion the previous year.Throughout the session, the stock f ...

The Tel Aviv Stock Exchange rose today. The Tel Aviv 35 Index rose 1.02% to 3,350.98 points, the Tel Aviv 125 Index rose 0.82% to 3,410.08 points; and the BlueTech Global Index fell 0.05% to 597.86 points. The All Bond corporate bond index fell 0.05% to 597.86 points. Turnover totalled NIS 3.84 billion in equities and NIS 4.13 billion in bonds. On the foreign exchange market, the representative shekel-dollar rate was set 0.276% lower from Tuesday, at NIS 3.250/$, and the representative shekel-euro rate wa ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its third-quarter 2025 financial results on Wednesday, with total revenue of $4.48 billion, beating analysts' expectations of $4.35 billion, according to Benzinga Pro.Revenues increased 3% year-over-year in U.S. dollars or 1% in local currency.Key brands continue to drive growth, with revenues up 33% in local currency to $830 million.Austedo (Huntington’s disease drug) sales increased 38% to $618 million. Increasing Austedo 2025 revenue outlook to $2. ...

Teva stock surged early Wednesday after the drugmaker reported adjusted earnings of 78 cents per share on $4.48 billion in third-quarter sales. On average, analysts polled by FactSet expected Teva Pharmaceutical (TEVA) to earn 68 cents per share on $4.38 billion in sales. During the year-earlier period, Teva reported earnings of 69 cents per share and $4.33 billion in sales. Teva hiked its guidance for Austedo. The company now expects the movement disorders drug to bring in $2.05 billion to $2.15 billion in ...

Teva Pharmaceutical Industries Ltd. stock rose 12% after the company reported stronger-than-expected third-quarter results, buoyed by robust growth in its branded drug portfolio. ...

周三，梯瓦制药(TEVA.US)盘前大涨近13%，报23.10美元。梯瓦制药Q3营收为44.8亿美元，市场预期为 43.4亿美元；调整后每股收益0.78美元，市场预期为0.68美元。公司预计2025财年全年收入区间为168亿 美元至170亿美元，而FactSet的预估为168.3亿美元。公司将2025财年调整后每股收益指引从2.50-2.60美 元上调至2.55-2.65美元，分析师预期为2.58美元。 ...

智通财经APP获悉，周三，梯瓦制药(TEVA.US)盘前大涨近13%，报23.10美元。梯瓦制药Q3营收为44.8 亿美元，市场预期为43.4亿美元；调整后每股收益0.78美元，市场预期为0.68美元。公司预计2025财年 全年收入区间为168亿美元至170亿美元，而FactSet的预估为168.3亿美元。公司将2025财年调整后每股 收益指引从2.50-2.60美元上调至2.55-2.65美元，分析师预期为2.58美元。 ...